- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06391177
A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily
May 9, 2024 updated by: Phathom Pharmaceuticals, Inc.
A Phase 1, Open-label Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily
The primary objective is to determine the pharmacokinetics (PK) of vonoprazan in breast milk of healthy lactating women who have received vonoprazan administered once daily for 4 consecutive days.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
8
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Phathom Medical Information
- Phone Number: 1-888-775-7248
- Email: medicalinformation@phathompharma.com
Study Locations
-
-
Nevada
-
Las Vegas, Nevada, United States, 89113
- Recruiting
- PPD Development, LP
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- The participant is a healthy lactating woman at least 18 years of age at the time of signing the informed consent form (ICF).
- The participant has delivered a normal term infant (at least 37 weeks gestation) and has been breastfeeding or actively pumping breast milk for at least 4 weeks postpartum prior to the first dose.
- The participant is willing to not breastfeed or otherwise use her breast milk during administration of vonoprazan and until at least 5 days after the last dose of the study drug.
- The participant has confirmed that her breastfed infant is able to feed from a bottle.
- The participant agrees to collect all breast milk from pre-dose to 24 hours after the last dose administration, using an electric pump.
- The participant is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead ECG results, and physical examination findings at Screening.
- Participants of childbearing potential must use an acceptable method of birth control (ie, diaphragm with spermicide, intrauterine device, condom with foam or vaginal spermicide, oral contraceptives, or abstinence) or be surgically sterile (ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy). All participants must have a negative pregnancy test at Screening and before the first dose of study drug (Baseline).
- The participant agrees to comply with all protocol requirements.
- The participant is able to provide written informed consent.
Exclusion Criteria:
- The participant has a positive pregnancy test at Screening or Baseline, is planning to become pregnant before, during, or within 4 weeks after participating in this study, or intends to donate ova during this time period, or is of childbearing potential and not using an effective contraceptive method.
- The participant has a history of breast implants, breast augmentation, or breast reduction surgery that significantly impacts breastfeeding or collection of milk from one or both breasts.
- The participant has signs or symptoms of mastitis or other condition that would prevent the collection of milk from one or both breasts.
- The participant has undergone prior esophageal and/or gastrointestinal surgeries that may affect study drug absorption.
- The participant has undergone surgery (other than cesarean section) within 30 days before the first dose of study drug.
- The participant has a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies at Screening.
- The participant has any other clinically significant findings on physical examination, clinical laboratory abnormalities, or ECG results that preclude participation in the study, as deemed by the investigator.
- The participant has used any prescription (excluding hormonal birth control) and/or over-the-counter medications (including cytochrome P450 3A4 inducers), including herbal or nutritional supplements, within 14 days before the first dose of study drug, and/or is expected to require any such medication during the course of the study until end of the Treatment Period. Use of multivitamins and acetaminophen (up to 2 g per day) is permissible.
- The participant has consumed grapefruit and/or grapefruit juice, Seville orange, or Seville orange-containing products (eg, marmalade) within 7 days before the first dose of study drug and/or is expected to be unable to abstain through the study.
- The participant is a smoker or has used nicotine or nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 6 months before the first dose of study drug.
- The participant has a history of alcohol abuse or drug dependency within 12 months before the first dose of study drug.
- The participant has a positive test result for drugs of abuse, alcohol, or cotinine (indicating active current smoking) at Screening, Baseline, or Day 4 (Check-in).
- The participant is involved in strenuous activity or contact sports within 24 hours before the first dose of study drug and during the study.
- The participant has a history of relevant drug and/or food allergies (ie, any significant food allergy that could preclude a standard diet in the clinical research unit).
- The participant has received study drug in another investigational study (including vonoprazan) within 30 days prior to start of the Screening Period.
- The participant has a history of hypersensitivity or allergies to vonoprazan or any of its formulation excipients (D-mannitol, microcrystalline cellulose, hydroxypropyl cellulose, fumaric acid, ascorbic acid, croscarmellose sodium, magnesium stearate, hypromellose, polyethylene glycol 8000, titanium dioxide, or ferric oxide red).
- In the opinion of the investigator, the participant is not suitable for entry into the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vonoprazan 20 mg
Participants will be administered once-daily doses of vonoprazan 20 mg for 4 consecutive days (Days 1 through 4).
|
Oral tablet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area Under the Drug Concentration-time Curve from Time 0 to 24 Hours (AUC0-24) Following the Last Dose of Vonoprazan in Breast Milk
Time Frame: From dosing on Day 4 through 24 hours postdose
|
From dosing on Day 4 through 24 hours postdose
|
Maximum Drug Concentration (Cmax) of Vonoprazan in Breast Milk
Time Frame: From dosing on Day 4 through 24 hours postdose
|
From dosing on Day 4 through 24 hours postdose
|
Minimum Drug Concentration (Cmin) of Vonoprazan in Breast Milk
Time Frame: From dosing on Day 4 through 24 hours postdose
|
From dosing on Day 4 through 24 hours postdose
|
Average Drug Concentration (Cavg) of Vonoprazan in Breast Milk
Time Frame: From dosing on Day 4 through 24 hours postdose
|
From dosing on Day 4 through 24 hours postdose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total Amount of Vonoprazan Excreted in Breast Milk
Time Frame: From dosing on Day 4 through 24 hours postdose
|
From dosing on Day 4 through 24 hours postdose
|
Percentage of Vonoprazan Excreted in Breast Milk Relative to Dose
Time Frame: From dosing on Day 4 through 24 hours postdose
|
From dosing on Day 4 through 24 hours postdose
|
Estimated Infant Daily Dose of Vonoprazan
Time Frame: From dosing on Day 4 through 24 hours postdose
|
From dosing on Day 4 through 24 hours postdose
|
Percentage Relative Infant Dose to the Maternal Dose of Vonoprazan
Time Frame: From dosing on Day 4 through 24 hours postdose
|
From dosing on Day 4 through 24 hours postdose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 1, 2024
Primary Completion (Estimated)
August 1, 2024
Study Completion (Estimated)
August 1, 2024
Study Registration Dates
First Submitted
April 25, 2024
First Submitted That Met QC Criteria
April 25, 2024
First Posted (Actual)
April 30, 2024
Study Record Updates
Last Update Posted (Actual)
May 10, 2024
Last Update Submitted That Met QC Criteria
May 9, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VONO-401
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Helicobacter Pylori Infection
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingHelicobacter Pylori Infection | Helicobacter Pylori EradicationBangladesh
-
Shandong UniversityRecruitingHelicobacter Pylori Infection | Patient Education | Helicobacter Pylori EradicationChina
-
Shandong UniversityCompletedHelicobacter Pylori Infection Helicobacter Pylori Eradication Patient EducationChina
-
Shanghai Jiao Tong University School of MedicineCompletedCure Rate of Helicobacter Pylori InfectionChina
-
Seoul National University Bundang HospitalRecruitingHelicobacter Pylori Infection | Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation | Helicobacter Pylori Associated Gastrointestinal Disease | Helicobacter Pylori Infection, Susceptibility toKorea, Republic of
-
The First Affiliated Hospital of Nanchang UniversityUnknownBacterial Infection Due to Helicobacter Pylori (H. Pylori) | Eradication Therapy of Helicobacter Pylori | Detection of Helicobacter PyloriChina
-
Tanta UniversityNot yet recruitingPersistent Helicobacter Pylori InfectionEgypt
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedHelicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method)Helicobacter Pylori Infection | Helicobacter Pylori gyrA Levofloxacin Resistance Mutation | Fecal Drug Resistance Gene Detection | Helicobacter Pylori Infection, Susceptibility toChina
-
National University Hospital, SingaporeUnknownHELICOBACTER PYLORI INFECTIONSSingapore
-
Kaohsiung Veterans General Hospital.Kaohsiung Medical University Chung-Ho Memorial HospitalCompletedHelicobacter Pylori InfectionTaiwan
Clinical Trials on Vonoprazan
-
TakedaCompleted
-
Phathom Pharmaceuticals, Inc.Completed
-
Phathom Pharmaceuticals, Inc.CompletedGastroesophageal Reflux DiseaseUnited States
-
Phathom Pharmaceuticals, Inc.CompletedGastroesophageal RefluxUnited States
-
Phathom Pharmaceuticals, Inc.CompletedHeartburn | Non-Erosive Gastro-Esophageal Reflux DiseaseUnited States
-
Phathom Pharmaceuticals, Inc.CompletedHeartburn | Non-Erosive Gastro-Esophageal Reflux DiseaseUnited States
-
TakedaCompleted
-
TakedaCompletedGastric Ulcer, Duodenal Ulcer, and Reflux EsophagitisJapan
-
Nanjing First Hospital, Nanjing Medical UniversityNot yet recruiting
-
Nanjing First Hospital, Nanjing Medical UniversityNot yet recruitingHelicobacter Pylori InfectionChina